

## NEUROMED: Final meeting, 18-19<sup>th</sup> June 2015

Institute of Biotechnology and Biomedicine  
 Dept. of Biochemistry and Molecular Biology  
 Parc de Recerca UAB, Mòdul B  
 Universitat Autònoma de Barcelona  
 E-08193 Bellaterra (Barcelona)

---

**11:00 h: Pre-meeting coffee**

**11:15 h: Welcome (Salvador Ventura and Javier Sancho)**

**11:30 h: Neuromed results: Developments, Partners Activities Reports and Indicators (15 min)**

Javier Sancho. *Universidad de Zaragoza. IUI BIFI.*

Salvador Ventura. *Universidad Autònoma de Barcelona*

Pau Bernadó. *INSERM. Délégation Régionale Languedoc-Roussillon Centre de Biochimie Structurale*

Marie Maddelein. *CNRS UMR5089 IPBS*

Maria Joao Saraiva. *Instituto de Biologia Molecular e Celular. IBMC*

Rui Brito. *Universidade de Coimbra*

**12:30 h: Short break**

**12:45 h: GT2. Phenylketonuria: Products, Results, and Communication (Javier Sancho).**

1. Computational design of molecules based on pharmacological chaperone IV using the three-dimensional structure obtained by diffraction X
2. Analysis of the route of folding and assembly of wild-type PHA and defective enzymes as well as the effects by chaperone IV and Kuvan
3. Synthesis and in vitro assay of new designed chaperones
4. Toxicity and efficacy in animal models

**13:00 h: GT3. Parkinson: Products, Results, and Communication (Salvador Ventura).**

1. Screening of chemical libraries and identification of inhibitors of of alpha-synuclein aggregation
2. Analysis of mechanism of alpha-synuclein inhibitors
3. Design, synthesis and in vitro analysis of fluorescent inhibitors capable of binding to to alpha-synuclein oligomers
4. Effect of alpha-synuclein oligomerization inhibitors in the neurodegenerative process
5. Analysis of fluorescent inhibitors in human specimens from patients with synucleopathies

**13:15 h: GT4. TTR Amyloidosis: Products, Results, and Communication (Rui Brito and Maria Joao Saraiva).**

1. Virtual and experimental screening of chemical libraries and identification of new pharmacological chaperones and inhibitors of TTR aggregation
2. Computational design and production of trans-suppressors of aggregation
3. Experimental analysis of the mode of action of pharmacological chaperones and the TTR trans-suppressors found in actions 1 and 2
4. Design, synthesis and test in vitro of conjugated inhibitors with affinity by TTR
5. Toxicity test in cell cultures of agents selected in actions 1-4
6. Toxicity and efficacy in mice models of the most promising pharmacological chaperones and inhibitors selected in action 5

**13:30 h: Neuromed Lunch**

**15:00 h: Neuromed Administrative and Management issues**

**GT 1. Coordination and Management: Products. Results. Communication (Javier Sancho).**

1. Coordination and technical strategy
2. Administrative and financial follow-up

**GT5. Monitoring and Evaluation: Products. Results. Communication (Javier Sancho).**

1. Monitoring of the implementation of the project
2. Evaluating of the implementation of the project.

**GT6. Advertising, information and capitalization: Products. Results. Communication (Javier Sancho).**

1. Advertising, information and capitalization, creation of a visual identity: logo, web, brochures and corporate communication plan.
2. A plan of capitalization of the results.
3. Organization of a seminar of capitalization and dissemination of results

**16:00 h: Conclusions and future plans (all partners)**

**17:00 h: End of Internal Final Meeting**

**20:00 h: Partner Dinner**